Publications by authors named "B Haben"
Article Synopsis
- The Prostate Cancer Outcomes (PCO) study is a multicenter initiative in Germany aimed at collecting patient-reported outcomes from men receiving local treatment for prostate cancer, as part of the Movember-funded TrueNTH Global Registry.
- The study involves certified prostate cancer centers that gather data on patient symptoms and function before treatment and again at 12 months after treatment, with a focus on data quality and response rates across different centers.
- As of the report's date, 44 centers have collected data on 3,094 patients, showing high recruitment rates primarily from radical prostatectomy cases, while highlighting the importance of continuous monitoring to ensure data quality in similar studies.
Purpose: The self-reported functional status (sr-FS) of prostate cancer (PCa) patients varies substantially between patients and health-care providers before treatment. Information about this issue is important for evaluating comparisons between health-care providers and to assist in treatment decision-making. There have been few reports on correlates of pretherapeutic sr-FS.
View Article and Find Full Text PDFPurpose: Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the usefulness of this test as a novel biomarker for GCT.
Patients And Methods: In a prospective, multicentric study, serum samples of 616 patients with testicular GCTs and 258 male controls were examined for serum levels of miRNA-371a-3p (miR levels) by quantitative polymerase chain reaction.
We present a case of a female patient who had a clinically suspected advanced urothelial carcinoma of the urethra. Histopathological examination surprisingly revealed a malignant tumor with morphological and immunohistochemical features of prostate cancer, leading to the diagnosis of the extremely rare entity of Skene's gland adenocarcinoma.
View Article and Find Full Text PDFIntroduction: International guidelines are ambivalent regarding the recommendations for the management of clinical stage 1 (CS1) seminoma.
Patients And Methods: During 2008-2013, 1,050 patients with seminoma CS1 were prospectively registered with regard to assessing management modality (radiotherapy, carboplatin, surveillance). Associations with tumor size, rete testis invasion, age, year of diagnosis, type of institution, and geographic location were assessed.